RATING

RECOMMENDATION

Strong Sell

  • ROFR Required
  • Available in Depository:

  • NSDL

  • CDSL

  • Available for Investment:

  • Primary

  • Secondary

RATING

RECOMMENDATION

Strong Sell

Business Type

Traditional Business

RATING

RECOMMENDATION

Strong Sell

Business Type

Traditional Business

Arch Pharmalabs Profit and Loss

Financial Year

Total Revenue
COGS
Gross Profit
Raw Materials
Power & Fuel Cost
Employee Cost
Sales & Administrative Expenses
Operating & Other Expenses
EBITDA
Depreciation/ Amortization
PBIT
Interest & Income
Interest & Expense
Other Items
PBT
Taxes & Other Items
Net Income
Diluted EPS
Basic EPS
DPS
Payout Ratio
FY 2018

24,743.78

-

24,743.78

18,440.56

-

4,868.33

-

27,712.12

-26,277.23

3,909.56

-30,186.79

32,325.01

8,251.85

-

-6,113.63

-

-6,113.63

-8.92

-8.92

-

-

FY 2019

51,477.83

-

51,477.83

41,685.87

-

6,384.97

-

-1,818.77

5,225.76

3,253.95

1,971.81

1,214.4

16,283.51

-

-13,097.3

34.02

-13,131.32

-8.64

-8.64

-

-

FY 2020

65,150.34

-

65,150.34

56,307.89

-

6,163.2

-

-3,085.11

5,764.36

3,030.06

2,734.3

1,712.97

20,466.52

-

-16,019.25

-69.21

-15,950.04

-10.5

-10.5

-

-

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ L

* denotes current year's data

  • Arch Pharmalabs Annual Reports

2019

2020